Too Many Clinical Trials Hamper Patient Recruitment In India; Complex Protocols Don't Help
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ballooning demand for clinical trials in India has kept the industry upbeat for the last few years but too much of it is leading to associated problems - one of which is patient recruitment
You may also be interested in...
Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
Clinical Research Is Booming In India But Are There Enough IRBs?
MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards